Statement by the Board of Directors of Abliva regarding the public cash offer from Pharming
The Board of Directors unanimously recommends the shareholders to accept the offer.
Press releases
Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain
-Results demonstrated that KL1333 was safe and well tolerated, with early signs of efficacy in patients with primary mitochondrial disease- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company ...
Abliva AB Interim Report January – September 2024
- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22
-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage compa ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the ...
Abliva AB Interim Report January – June 2024
FALCON Positioned for Success Following Analysis by Independent Committee ⎮ Strong Safety Profile Confirmed, and Both Primary Endpoints Passed Futility
Positive interim analysis in Abliva’s FALCON study triggers convertible loan conversion
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the convertible loan of SEK 42 ...
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 103,149,954, as a result of a preferential rights issue announced by the Board of ...
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease
-With 24 weeks of dosing complete, Abliva remains on track to report the interim analysis in early Q3 2024- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for [&helli ...
Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.
Abliva AB Interim Report January – March 2024
SEK 46 million raised through preferential rights issue | Preparations for the interim analysis ongoing